Flex Pharma (NASDAQ:FLKS) Earning Somewhat Negative Press Coverage, Accern Reports

News headlines about Flex Pharma (NASDAQ:FLKS) have been trending somewhat negative on Tuesday, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Flex Pharma earned a daily sentiment score of -0.16 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the stock’s share price in the next few days.

Shares of Flex Pharma (NASDAQ:FLKS) opened at 3.90 on Tuesday. The company’s market cap is $66.41 million. The firm’s 50 day moving average is $3.75 and its 200 day moving average is $4.00. Flex Pharma has a 12 month low of $3.01 and a 12 month high of $12.68.

Flex Pharma (NASDAQ:FLKS) last announced its earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.13. Flex Pharma had a negative net margin of 3,043.70% and a negative return on equity of 60.50%. The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.38 million. On average, equities analysts predict that Flex Pharma will post ($2.41) earnings per share for the current year.

A number of equities research analysts have weighed in on FLKS shares. Zacks Investment Research downgraded Flex Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, May 23rd. Jefferies Group LLC decreased their price objective on Flex Pharma from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, May 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. Flex Pharma has an average rating of “Buy” and a consensus price target of $15.40.

ILLEGAL ACTIVITY WARNING: “Flex Pharma (NASDAQ:FLKS) Earning Somewhat Negative Press Coverage, Accern Reports” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://sportsperspectives.com/2017/07/25/flex-pharma-nasdaqflks-earning-somewhat-critical-press-coverage-report-finds-updated.html.

Flex Pharma Company Profile

Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.

Insider Buying and Selling by Quarter for Flex Pharma (NASDAQ:FLKS)

Receive News & Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply